Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease (Q37563447)

21 August 2017

1 reference

title

Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

21 August 2017

1 reference

inferred from title

budesonide/formoterol

1 reference

Katherine A Lyseng-Williamson

inferred from title

author

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

21 August 2017

1 July 2009

1 reference

21 August 2017

1 reference

21 August 2017

69

1 reference

21 August 2017

11

1 reference

21 August 2017

1459-1470

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200969110-00005

21 August 2017

0 references

cites work

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

12 December 2020

Budesonide/Formoterol pressurized metered-dose inhaler

1 reference

12 December 2020

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

1 reference

12 December 2020

A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease

1 reference

12 December 2020

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

12 December 2020

Budesonide/formoterol: in chronic obstructive pulmonary disease

1 reference

12 December 2020

Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults

1 reference

12 December 2020

Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

1 reference

12 December 2020

Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease

1 reference

12 December 2020

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

12 December 2020

Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.

1 reference

12 December 2020

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

12 December 2020

Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid

1 reference

12 December 2020

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

1 reference

12 December 2020

Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

12 December 2020

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

1 reference

12 December 2020

Safety of long-acting beta-agonists in stable COPD: a systematic review

1 reference

12 December 2020

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

12 December 2020

Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies

1 reference

12 December 2020

10.2165/00003495-200969110-00005

Identifiers

DOI

1 reference

PubMed ID

19634924

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

19634924